Detalles de la búsqueda
1.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clin Infect Dis
; 76(5): 861-870, 2023 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36259527
2.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis
; 77(7): 991-1009, 2023 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37207617
3.
A truncated HIV Tat demonstrates potent and specific latency reversal activity.
Antimicrob Agents Chemother
; 67(11): e0041723, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37874295
4.
Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study.
Clin Gastroenterol Hepatol
; 21(3): 713-722.e3, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35436624
5.
Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
J Antimicrob Chemother
; 78(8): 1929-1933, 2023 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37303236
6.
Are unknown co-medications, over-the-counter and off-label drug use still problems among people living with HIV? Results from a transversal survey in 23 centres in France.
J Antimicrob Chemother
; 78(11): 2731-2734, 2023 11 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37757452
7.
Proportion of APOBEC3-induced defective HIV DNA after 1â year of dolutegravirâ+âlamivudine simplification in the ANRS 167 LAMIDOL trial.
J Antimicrob Chemother
; 78(12): 2995-3002, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37930812
8.
Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort.
J Antimicrob Chemother
; 78(3): 757-768, 2023 03 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36683307
9.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
J Infect Dis
; 225(3): 502-509, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34415048
10.
More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy.
J Antimicrob Chemother
; 77(8): 2251-2256, 2022 07 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35640662
11.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
J Antimicrob Chemother
; 77(7): 1980-1988, 2022 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35411401
12.
Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area.
Eur J Clin Microbiol Infect Dis
; 41(3): 445-454, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34997388
13.
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial.
AIDS Res Ther
; 19(1): 4, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35033092
14.
Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus.
Clin Infect Dis
; 72(9): e215-e223, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32686834
15.
No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.
J Antimicrob Chemother
; 76(6): 1553-1557, 2021 05 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33693680
16.
Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir.
J Antimicrob Chemother
; 76(8): 2148-2152, 2021 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33930161
17.
Prevalence of genotypic baseline risk factors for cabotegravirâ+ârilpivirine failure among ARV-naive patients.
J Antimicrob Chemother
; 76(11): 2983-2987, 2021 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34015097
18.
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
J Antimicrob Chemother
; 76(7): 1893-1897, 2021 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33855355
19.
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
J Antimicrob Chemother
; 76(2): 477-481, 2021 01 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33099638
20.
Pharmacological data of a successful 4-days-a-week regimen in HIV antiretroviral therapy (ANRS 162-4D trial).
Br J Clin Pharmacol
; 87(4): 1930-1939, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33010058